Trends in Dual Antiplatelet Therapy of Aspirin and Clopidogrel and Outcomes in Ischemic Stroke Patients Noneligible for POINT/CHANCE Trial Treatment.
Joon Tae KimJi Sung LeeHyunsoo KimBeom Joon KimKeon-Joo LeeJong-Moo ParkKyusik KangSoo Joo LeeJae Guk KimJae Kwan ChaDae-Hyun KimTai Hwan ParkKyung Bok LeeJun LeeKeun-Sik HongYong-Jin ChoHong Kyun ParkByung-Chul LeeKyung Ho YuMi-Sun OhDong-Eog KimJay Chol ChoiJee Hyun KwonWook-Joo KimDong-Ick ShinKyu Sun YumSung Il SohnJeong-Ho HongSang-Hwa LeeMan-Seok ParkWi-Sun RyuKwang Yeol ParkJuneyoung LeeJeffrey L SaverHee Joon BaePublished in: Journal of the American Heart Association (2024)
Use of DAPT-AC in stroke patients with stroke ineligible for recent DAPT clinical trials increased markedly and steadily after CHANCE publication in 2013, reaching deployment in nearly 4 of every 5 patients by 2022. The secondary prevention in patients with ischemic stroke seems to be gradually improving, possibly due to the enhancement of risk factor control.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- end stage renal disease
- clinical trial
- atrial fibrillation
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- low dose
- cardiovascular disease
- patient reported outcomes
- coronary artery disease
- metabolic syndrome
- blood brain barrier
- phase ii
- cardiovascular events